Bulletin
Investor Alert

Tiziana Life Sciences Ltd.

NAS: TLSA

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Tiziana Life Sciences Ltd.

After Hours

 --Quotes are delayed by 20 min

Aug 12, 2022, 6:22 p.m.

TLSA
/zigman2/quotes/207307745/composite

$

0.70

Change

+0.03 +4.46%

Volume

Volume 430

Quotes are delayed by 20 min

/zigman2/quotes/207307745/composite

Previous close

$ 0.72

$ 0.67

Change

-0.05 -6.29%

Day low

Day high

$0.67

$0.74

Open

52 week low

52 week high

$0.53

$2.10

Open

Company Description

Tiziana Life Sciences Ltd. engages in the research and development of biotechnological and pharmaceutical products. It develops transformative therapies for autoimmune and inflammatory diseases, degenerative diseases, and cancer related to the liver. Its clinical pipeline includes Foralumab, Anti IL...

Tiziana Life Sciences Ltd. engages in the research and development of biotechnological and pharmaceutical products. It develops transformative therapies for autoimmune and inflammatory diseases, degenerative diseases, and cancer related to the liver. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.

Valuation

Price to Book Ratio

2.38

Enterprise Value to EBITDA

-3.38

Efficiency

Liquidity

Current Ratio

6.45

Quick Ratio

6.45

Cash Ratio

5.59

Profitability

Return on Assets

-39.16

Return on Equity

-45.14

Return on Total Capital

-54.35

Capital Structure

Total Debt to Total Assets

2.78

Officers and Executives

Name Age Officer Since Title
Mr. Gabriele Marco Antonio Cerrone 48 1998 Executive Chairman
Ms. Keeren Shah 45 2020 Finance Director
Dr. Vaseem A. Palejwala - 2017 Director-Clinical Operations
Dr. Kunwar Shailubhai 64 2008 CEO, Executive Director & Chief Scientific Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
10/05/2021 Gabriele Marco Antonio Cerrone
60,000   Acquisition at $0.52 per share. 31,050
10/04/2021 Gabriele Marco Antonio Cerrone
60,000   Acquisition at $0.55 per share. 33,000
10/04/2021 Gabriele Marco Antonio Cerrone
60,000   Acquisition at $0.5 per share. 30,000
10/01/2021 Gabriele Marco Antonio Cerrone
37,500   Acquisition at $0.49 per share. 18,300
09/27/2021 Gabriele Marco Antonio Cerrone
100,000   Acquisition at $0.52 per share. 52,000
05/20/2021 Gabriele Marco Antonio Cerrone
10,000   Acquisition at $0.71 per share. 7,100
12/09/2020 Gabriele Marco Antonio Cerrone
38,000   Acquisition at $0.78 per share. 29,640
11/18/2020 Gabriele Marco Antonio Cerrone
45,000   Acquisition at $0.84 per share. 37,800
02/03/2020 Gabriele Marco Antonio Cerrone
5,000   Acquisition at $2.37 per share. 11,850
01/13/2020 Gabriele Marco Antonio Cerrone
28,500   Acquisition at $0.43 per share. 12,255
12/31/2019 Gabriele Marco Antonio Cerrone
12,500   Acquisition at $2.79 per share. 34,875
/news/latest/company/us/tlsa

MarketWatch News on TLSA

  2. Tesla Hit a New High. No, It Was TLSA. Confused?

    6:34 p.m. July 15, 2020

    - Barron's Online

  3. Tesla's stock drops 3.3% premarket, after soaring 9.0% Wednesday to record high

    8:27 a.m. June 11, 2020

    - Tomi Kilgore

/news/nonmarketwatch/company/us/tlsa

Other News on TLSA

  1. Tiziana appoints former Endo exec as chief medical officer

    7:05 a.m. July 18, 2022

    - Seeking Alpha

  2. Tiziana Life Sciences CEO Kunwar Shailubhai resigns

    4:55 p.m. July 15, 2022

    - Seeking Alpha

  3. General Motors Is Catching Up To Tesla

    9:18 a.m. July 6, 2022

    - Seeking Alpha

  4. Nasdaq sends non-compliance notice to Tiziana Life Sciences

    5:31 p.m. June 17, 2022

    - Seeking Alpha

  7. Talon Metals And The Defense Production Act

    9:04 a.m. April 4, 2022

    - Seeking Alpha

  9. KNDI, LILM and ADN among mid- day movers

    12:38 p.m. March 24, 2022

    - Seeking Alpha

  12. Stock Split Watch: Is Amazon Next?

    7:16 a.m. Dec. 23, 2021

    - Motley Fool

  13. Warning: TLSA is at high risk of performing badly

    9:55 a.m. Oct. 12, 2021

    - Seeking Alpha

  14. TLSA is at high risk of performing badly

    4:30 a.m. Oct. 12, 2021

    - Seeking Alpha

  17. GSAT, GDP and ASMB among mid-day movers

    1:09 p.m. Sept. 2, 2021

    - Seeking Alpha

  18. DQ, BTBT and GOTU among pre market gainers

    8:34 a.m. Sept. 2, 2021

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

Tiziana Life Sciences Ltd.

55 Park Lane

London, Greater London W1K 1NA

Phone

44 2074952379

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

View SEC Filings

Revenue

N/A

Net Income

$-23.42M

Employees

8.00

Annual Report for TLSA

/news/pressrelease/company/us/tlsa

Press Releases on TLSA

  3. Tiziana Life Sciences Announces Resignation of CEO

    4:15 p.m. July 15, 2022

    - GlobeNewswire

  4. Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice

    4:30 p.m. June 17, 2022

    - GlobeNewswire

  18. AccuStem Sciences, Inc. Appoints New Executive Leadership Team

    8:00 a.m. March 4, 2022

    - GlobeNewswire

  19. StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort

    10:06 a.m. March 1, 2022

    - GlobeNewswire

  21. Loading more headlines...
Link to MarketWatch's Slice.